Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
Date:3/7/2013

cash423

2,458Short-term investments175,245

128,054Accounts receivable, net99,578

72,736Inventories47,774

45,351Prepaid expenses and other current assets18,807

15,133Total current assets395,960

335,100Non-current assets:Goodwill32,561

34,701Property, plant and equipment, net264,381

245,694Long-term investments14,015

4,335Intangible assets, net7,268

10,568Land use rights5,564

5,488Deferred tax assets3,037

8,499Other non-current assets19,749

19,469Total non-current assets346,575

328,754Total assets742,535

663,854Liabilities and equity:Current liabilities:Short-term and current portion of long-term debt59,089

28,661Accounts payable21,808

22,803Accrued expenses27,411

20,913Deferred revenue17,052

15,881Advanced subsidies9,265

6,417Other taxes payable1,581

2,196Convertible notes-

35,864Other current liabilities11,215

10,018Total current liabilities147,421

142,753Non-current liabilities:Long-term debt, excluding current portion5,697

1,646Advanced subsidies2,663

3,215Long-term payable732

3,944Other non-current liabilities7,799

6,570Total non-current liabilities16,891

15,375Total liabilities164,312

158,128Equity:Ordinary shares ($0.02 par value, 5,002,550,000

authorized, 570,489,352 and 561,121,002 issued and

outstanding as of December 31, 2011, and December 31,

2012, respectively) 11,222

11,410Additional paid-in capital331,715

345,832Retained earnings188,604

103,159Accumulated other comprehensive income46,682

45,325Total equity578,223

505,726Total liabilities and equity742,535

663,854 WUXI PHARMATECH (CAYMAN) INC.UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(In thousands of U.S. dollars
'/>"/>

SOURCE Wuxi PharmaTech Co. Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
2. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
3. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
4. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
5. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
6. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
7. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
8. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
9. WuXi PharmaTech Announces Second-Quarter 2012 Results
10. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
11. WuXi PharmaTech Announces First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Rock Creek Pharmaceuticals, Inc. (NASDAQ: ... announced that the Food and Drug Administration ("FDA"), has ... on RCP,s Investigational New Drug ("IND") application before granting ... the US. Dr. Chris Chapman , ... comments on our IND. When we receive the agency,s ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... GREEN BAY, Wis., Sept. 16 Top researchers at ... Center in Dallas are exploring the clinical applications of ... potency, and bioavailability. Previous studies have ... than other forms of curcumin, and had a retention ...
... Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic... -- REGENSBURG, Germany, September ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
Cached Medicine Technology:BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 2Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 3Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 4Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 5Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 6Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 7Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 8
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... 2014 Recently, MyDressCity.com, one of the ... occasion outfits, has released its new range of ... products are available at discounted prices. Worldwide clients can ... , In the company’s online shop, there are plenty ... are made with great materials. MyDressCity.com’s hot items are ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... , NAPA, Calif., Aug. 19 Dey ... today issued an advisory regarding two lots of its Albuterol Sulfate ... that was stolen in McKinney, Texas. , , ... brand name "DEY" and contains thirty 3ml single-dose vials. The lot ...
... , , , ... released the following statement after President Obama said that it,s ... the health care reform plans. , , ... "Tonight, President Obama deliberately misled the American people by ...
... , , , ... one of four companies to have been awarded a contract to ... The contract becomes effective October 1, 2009. , , ... work with the State of Arizona and offer our innovative health ...
... Aug. 19 (HealthDay News) -- People with lung cancer who ... a drug called Tarceva, which is believed to work well ... who take the drug, new research has found. , According ... 20 issue of the New England Journal of Medicine ...
... NEW YORK, Aug. 19 One of the few bright spots of ... and HBA Global Expo ( www.hb a e ... activists to deliver a Keynote Presentations on Tuesday, September 15, 2009 at ... New York. Horst M. Rechelbacher, founder of Intelligent Nutrients and ...
... a novel robot-assisted endoscopic technique, a team of surgeons ... has successfully treated 200 consecutive patients with thyroid cancer. ... cosmetic benefits that the traditional open operation does not ... Journal of the American College of Surgeons . ...
Cached Medicine News:Health News:Dey Issues Advisory 2Health News:President Obama Misleads on Abortion Funding in Health Care Reform 2Health News:CIGNA Awarded State of Arizona Health Care Contract 2Health News:Gene Mutation Improves Response to Lung Cancer Drug 2Health News:Gene Mutation Improves Response to Lung Cancer Drug 3Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 2Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 3Health News:New robot-assisted surgical method found successful for treatment of thyroid cancer 2
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: